Cell Host Microbe:口腔核梭杆菌或可诱发结直肠癌

2013-09-06 佚名 生物无忧

来自美国凯斯西储大学牙科学院的研究人员发现,一种常见的口腔细菌能够引发结肠直肠癌。这一发现为找到方法来预防和治疗这种癌症提供了一个新的研究方向。 牙科学院的牙周病学教授Yiping Han是这项研究的主要调查者,她说:“我们发现,结肠直肠癌的发生与细菌的感染有关。这一发现为治疗和预防这种癌症提供了潜在的新诊断工具和治疗方法。” 这项研究的结果被发表在Cell Host & Microb

来自美国凯斯西储大学牙科学院的研究人员发现,一种常见的口腔细菌能够引发结肠直肠癌。这一发现为找到方法来预防和治疗这种癌症提供了一个新的研究方向。

牙科学院的牙周病学教授Yiping Han是这项研究的主要调查者,她说:“我们发现,结肠直肠癌的发生与细菌的感染有关。这一发现为治疗和预防这种癌症提供了潜在的新诊断工具和治疗方法。”

这项研究的结果被发表在Cell Host & Microbe上。该结果与其他调查小组的另一个研究结果共同阐明了:细菌如何加速了癌变细胞的积累。

同时,研究人员还找到了预防这种微生物的方法。这种细菌名为具核梭杆菌(Fusobacterium nucleatum, Fn),可以粘附在结肠癌细胞上,潜在的触发一连串变化来引发癌症。

这些发现从2011年开始起步。在2011年,Han和她的研究小组确定了位于Fn表面的一个名为FadA的粘附分子,它可以结合VE-钙粘蛋白。VE-钙粘蛋白(VE-cadherin)是钙粘蛋白家族的一个成员,是位于血管上的一个细胞受体。

当Han完成了关于FadA和VE-cadherin的研究工作时,来自哈佛大学和哥伦比亚大学的研究者们也发现了恶性肿瘤表面存在着比正常组织表面更多的Fn. Han说,当了解到这些结果时,她立刻怀疑Fn或许能像在血管中一样在结肠中发挥作用——与结肠里的细胞相互作用。因此,之后她便将实验室的研究重心转向了结肠直肠癌。

因为她的实验室能够追踪Fn结合血管上VE-cadherin受体的能力,因此发现FadA与结肠细胞中VE-cadherin受体的结合过程并没有花费太长时间。

他们发现,FadA与VE-cadherin的结合启动了一个名为 -连环蛋白( -catenin)的蛋白质。 -catenin有很多功能,在这里它对癌症的发生有两个贡献:一是促发炎症反应改变了免疫系统,另一个则是刺激了癌细胞的生长。

Han实验室设计了一个新的合成肽来抑制FadA与E-cadherin的结合,进而抑制了促发癌症的其它过程。

他们还发现,在癌前、恶性的结肠息肉中,FadA基因的水平是正常组织的10-100倍。

因此,Han说:“FadA能够成为一个诊断标志物,用于结肠直肠癌的早期检测。它还可以检测治疗是否有效的减少了肠道和口腔中的Fn.”

此研究相关工作的专利申请已经提交。

Han强调,这些结果告诉我们注重口腔健康的重要性。在牙龈疾病发生时,Fn这种危险细菌会大大增加。

原文阅读

Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW.Fusobacterium nucleatum Promotes Colorectal Carcinogenesis by Modulating E-Cadherin/β-Catenin Signaling via its FadA Adhesin.Cell Host Microbe. 2013 Aug 14;14(2):195-206.

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1958917, encodeId=4a91195891e36, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat May 10 06:51:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084087, encodeId=4649208408e36, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Nov 28 16:51:00 CST 2013, time=2013-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868679, encodeId=b34918686e94b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Mar 20 11:51:00 CST 2014, time=2014-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857305, encodeId=fa11185e305f2, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Thu Dec 19 17:51:00 CST 2013, time=2013-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975760, encodeId=683a19e576027, content=<a href='/topic/show?id=6cf1624888e' target=_blank style='color:#2F92EE;'>#梭杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62488, encryptionId=6cf1624888e, topicName=梭杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Fri Jun 27 17:51:00 CST 2014, time=2014-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452647, encodeId=168d145264e0a, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Sep 08 07:51:00 CST 2013, time=2013-09-08, status=1, ipAttribution=)]
    2014-05-10 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1958917, encodeId=4a91195891e36, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat May 10 06:51:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084087, encodeId=4649208408e36, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Nov 28 16:51:00 CST 2013, time=2013-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868679, encodeId=b34918686e94b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Mar 20 11:51:00 CST 2014, time=2014-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857305, encodeId=fa11185e305f2, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Thu Dec 19 17:51:00 CST 2013, time=2013-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975760, encodeId=683a19e576027, content=<a href='/topic/show?id=6cf1624888e' target=_blank style='color:#2F92EE;'>#梭杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62488, encryptionId=6cf1624888e, topicName=梭杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Fri Jun 27 17:51:00 CST 2014, time=2014-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452647, encodeId=168d145264e0a, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Sep 08 07:51:00 CST 2013, time=2013-09-08, status=1, ipAttribution=)]
    2013-11-28 xjy02
  3. [GetPortalCommentsPageByObjectIdResponse(id=1958917, encodeId=4a91195891e36, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat May 10 06:51:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084087, encodeId=4649208408e36, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Nov 28 16:51:00 CST 2013, time=2013-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868679, encodeId=b34918686e94b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Mar 20 11:51:00 CST 2014, time=2014-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857305, encodeId=fa11185e305f2, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Thu Dec 19 17:51:00 CST 2013, time=2013-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975760, encodeId=683a19e576027, content=<a href='/topic/show?id=6cf1624888e' target=_blank style='color:#2F92EE;'>#梭杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62488, encryptionId=6cf1624888e, topicName=梭杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Fri Jun 27 17:51:00 CST 2014, time=2014-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452647, encodeId=168d145264e0a, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Sep 08 07:51:00 CST 2013, time=2013-09-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1958917, encodeId=4a91195891e36, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat May 10 06:51:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084087, encodeId=4649208408e36, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Nov 28 16:51:00 CST 2013, time=2013-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868679, encodeId=b34918686e94b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Mar 20 11:51:00 CST 2014, time=2014-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857305, encodeId=fa11185e305f2, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Thu Dec 19 17:51:00 CST 2013, time=2013-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975760, encodeId=683a19e576027, content=<a href='/topic/show?id=6cf1624888e' target=_blank style='color:#2F92EE;'>#梭杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62488, encryptionId=6cf1624888e, topicName=梭杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Fri Jun 27 17:51:00 CST 2014, time=2014-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452647, encodeId=168d145264e0a, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Sep 08 07:51:00 CST 2013, time=2013-09-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1958917, encodeId=4a91195891e36, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat May 10 06:51:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084087, encodeId=4649208408e36, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Nov 28 16:51:00 CST 2013, time=2013-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868679, encodeId=b34918686e94b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Mar 20 11:51:00 CST 2014, time=2014-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857305, encodeId=fa11185e305f2, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Thu Dec 19 17:51:00 CST 2013, time=2013-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975760, encodeId=683a19e576027, content=<a href='/topic/show?id=6cf1624888e' target=_blank style='color:#2F92EE;'>#梭杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62488, encryptionId=6cf1624888e, topicName=梭杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Fri Jun 27 17:51:00 CST 2014, time=2014-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452647, encodeId=168d145264e0a, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Sep 08 07:51:00 CST 2013, time=2013-09-08, status=1, ipAttribution=)]
    2014-06-27 bioon1
  6. [GetPortalCommentsPageByObjectIdResponse(id=1958917, encodeId=4a91195891e36, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat May 10 06:51:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084087, encodeId=4649208408e36, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Nov 28 16:51:00 CST 2013, time=2013-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868679, encodeId=b34918686e94b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Mar 20 11:51:00 CST 2014, time=2014-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857305, encodeId=fa11185e305f2, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Thu Dec 19 17:51:00 CST 2013, time=2013-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975760, encodeId=683a19e576027, content=<a href='/topic/show?id=6cf1624888e' target=_blank style='color:#2F92EE;'>#梭杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62488, encryptionId=6cf1624888e, topicName=梭杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Fri Jun 27 17:51:00 CST 2014, time=2014-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452647, encodeId=168d145264e0a, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Sep 08 07:51:00 CST 2013, time=2013-09-08, status=1, ipAttribution=)]

相关资讯

Ann Surg:术前放化疗不增加直肠癌吻合口瘘风险

在过去十年间,对于术前CRT对AL的影响,相关数据彼此矛盾。对此,韩国延世大学的Woong Sub Koom博士等人进行了一项研究,该研究通过倾向性评分匹配法,评价了在直肠癌切除术前进行的放化疗(CRT)对术后吻合口瘘的影响。这项研究结果发表于2013年4月17日在线出版的《外科学年鉴》(Annals of Surgery)杂志上。最终通过倾向性评分匹配分析发现,术前CRT并未增加接受LAR治疗的

ASCRS 2013:meta分析显示根治性切除术和局部切除术治疗早期直肠癌疗效基本相当

美国结直肠外科医师协会(ASCRS)2013年会上公布的一项系统综述和meta分析显示,根治性切除术和局部切除术这2种手术治疗方法对早期直肠癌患者的疗效基本相当。 上述结论的依据是涉及2,855例T1N0M0期直肠腺癌患者的13项研究。所有这些研究均发表于1997年之后,当时,全直肠系膜切除和现代局部切除技术已应用于临床。 主要研究者、加拿大西安大略大学外科医生Sami A.&nbs

关于印发胃癌等五种恶性肿瘤规范化诊疗指南的通知

关于印发胃癌等五种恶性肿瘤规范化诊疗指南的通知 卫办医管发〔2013〕33号中华人民共和国国家卫生和计划生育委员会     各省、自治区、直辖市卫生厅局(卫生和计划生育委员会),新疆生产建设兵团卫生局:        为进一步推进农村居民重大疾病医疗保障工作,加强恶性肿瘤的规范化诊疗管理,规范诊疗行为,提高诊疗质量,控制诊疗费用,我

DDW 2013:二甲双胍或降低糖尿病患者结直肠癌风险

  奥兰多——在消化疾病周(DDW)上发表的一项Meta分析显示,二甲双胍可能与2型糖尿病患者的结直肠癌(CRC)风险降低有关。   罗切斯特梅奥医院的Siddharth Singh医生报告称,磺酰脲类和胰岛素均与CRC风险降低无关,反而显示出风险增加的不显著趋势。未观察到CRC与噻唑烷二酮(TZD)类药物之间有关。   糖尿病是明确的CRC危险因素,而且临床前和观察性研究已显示,抗糖尿病药物

AJG:荟萃分析显示便秘不会增加结直肠癌发病率

有研究提出长期便秘可能会降低结直肠癌患者的生存率。但其原因尚不清楚,可能与结直肠的解剖结构和病理特征有关。如长期慢性便秘能导致直肠脱垂、痔疮、肛裂以及憩室性疾病等,导致结直肠压力增高及结肠通过时间延长,增加了代谢产物对结直肠粘膜的刺激,而这一现象也是导致结直肠癌发生的原因之一。究竟便秘与结直肠癌之间是否存在相关性呢?英国利兹大学医学院胃肠病学研究所的Andrew M等人对发表日期截止于2012年7

Ann Oncol:短期放疗再加贝伐和化疗对原发转移性直肠癌具有良好疗效

一项在线发表于Annals of Oncology的研究评估了短期放疗+新辅助化疗(贝伐珠单抗-卡培他滨-奥沙利铂)+ 根治性手术治疗原发IV期直肠癌患者的疗效和耐受性(Ann Oncol. 2013 Jul;24(7):1762-9. ) 研究设计该研究受试者为原发转移性直肠癌成人患者。患者接受放射治疗(5×5 Gy),继以贝伐珠单抗(7.5 mg/kg,静脉给药, d1)+奥沙利铂(